Frontiers in Immunology (Nov 2017)

Will a mAb-Based Immunotherapy Directed against Cancer Stem Cells Be Feasible?

  • Silvia Santamaria,
  • Marisa Delgado,
  • Leonor Kremer,
  • Jose A. Garcia-Sanz

DOI
https://doi.org/10.3389/fimmu.2017.01509
Journal volume & issue
Vol. 8

Abstract

Read online

The cancer stem cell (CSC) hypothesis suggests that within a tumor, there is a small subpopulation of cells with stem cell properties responsible for tumor maintenance and metastasis generation. This hypothesis also implies that new antitumor drugs, rather than targeting the bulk of the tumor mass, would be more effective if they directly targeted the CSC subpopulation. The CSCs from several types of tumors have been identified with mAbs recognizing surface antigens in these cells; however, antigens specifically or exclusively expressed in the CSC population have not yet been identified. Thus, questioning the possibility of using therapeutic antibodies directed against the CSCs. Here, we review the possibilities of using antibodies directly targeting the CSCs as therapeutic agents in the form of naked antibodies, antibodies conjugated to nanoparticles, or antibody cocktails.

Keywords